New cancer drug enters first human testing
NCT ID NCT05678998
Summary
This was the first-ever study in people of an experimental drug called WTX-330, designed to treat advanced cancers that have spread or stopped responding to standard treatments. The small trial enrolled 25 adults with advanced solid tumors or lymphoma to find a safe dose and see how the body processes the drug. The main goals were to check for serious side effects and see if the treatment showed any early signs of helping shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States
-
Facility Name: Roswell Park Comprehensive Cancer Care
Buffalo, New York, 14203, United States
-
HonorHealth
Scottsdale, Arizona, 85258, United States
-
Indiana University
Indianapolis, Indiana, 46202, United States
-
Mass General Hospital
Boston, Massachusetts, 02114, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Providence Cancer Institute Franz Clinic
Portland, Oregon, 97213, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.